Jennifer Leddon

Jennifer Lynn Leddon , MD,PhD

Assistant Professor

Vontz Center

COM IM Hematology/Oncology Division - 0562

Education

MD/PhD: University of Cincinnati

BS: University of Alabama Birmingham,

Certifications

American Board of Internal Medicine (Certification Date: 08-16-2019 )

Clinical Interests

Lung Cancer

Hematology and Oncology

Medical Oncology

Oncology

Specialities

Internal Medicine

Research and Practice Interests

Research Support

Grant: #CF33-hNIS-002 04-01-2022 -03-31-2025 Imugene Limited A Phase I, Dose Escalation Safety and Tolerability Study of VAXINIA (CF33-hNIS), Administered Intratumorally or Intravenously as a Monotherapy or in Combination with Pembrolizumab in Adult Patients Role:PI 721197.85 Hold Level:Industry

Grant: #CF33-hNIS-002 04-01-2022 -03-31-2025 Imugene Limited A Phase I, Dose Escalation Safety and Tolerability Study of VAXINIA (CF33-hNIS), Administered Intratumorally or Intravenously as a Monotherapy or in Combination with Pembrolizumab in Adult Patients Role:PI 721197.85 Hold Level:Industry

Publications

Published Abstracts

Leddon, J.L., Chen, C.Y., Currier, M.A., Wang, P.Y., Jung, F.A., Denton, N.L., Cripe, K.M., Haworth, K.B., Arnold, M.A., Gross, A.C. and Eubank, T.D. (2015. ) Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity .[Abstract]Molecular therapy oncolytics, 1 ,14010

Currier, M.A., Eshun, F.K., Sholl, A., Chernoguz, A., Crawford, K., Divanovic, S., Boon, L., Goins, W.F., Frischer, J.S., Collins, M.H. and Leddon, J.L. (2013. ) VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells .[Abstract]Molecular Therapy, 21(5) ,1014

Browne, A.W., Leddon, J.L., Currier, M.A., Williams, J.P., Frischer, J.S., Collins, M.H., Ahn, C.H. and Cripe, T.P. (2011. ) Cancer screening by systemic administration of a gene delivery vector encoding tumor-selective secretable biomarker expression .[Abstract]PloS one, 6(5) ,19530